🧬 Aging Wiki

venous-valve-reconstruction

Properties1
aliasesartificial venous valve, prosthetic venous valve, bioprosthetic venous valve, venous valve repair, valvuloplasty, neovalve, venous valve transplant, VenoValve, enVVe, BlueLeaf, deep venous reconstruction

8 min read

Venous valve reconstruction and artificial venous valves

The attempt to repair or replace an incompetent deep venous valve to abolish reflux and lower ambulatory venous hypertension. The indication is deep venous reflux — post-thrombotic syndrome (PTS) and advanced chronic venous insufficiency (CEAP C4b–C6) — not cosmetic or superficial varicose veins, which are managed by ablation/sclerotherapy (see chronic-venous-disease § Interventions). This page is the engineering counterpart to the venous-valve biology on veins.

The core engineering problem — why it’s so hard

The venous environment is uniquely hostile to a prosthesis: low flow velocity, low pressure, and high thrombogenicity. A prosthetic leaflet sits in slow-moving blood with little washout, so any thrombogenic surface seeds clot; historically prosthetic venous valves have thrombosed, fibrosed into immobility, or migrated. A systematic review of the 2012–2020 device literature catalogued the recurring failure modes — regurgitation, migration, leakage — and concluded the field remains “away from the ideal valve.”1 As of May 2026 there is still no FDA-approved prosthetic venous valve (see § Current status).

A second cross-cutting problem: several devices show clinical-score improvement (rVCSS) without commensurate hemodynamic (reflux-time) correction, which single-arm open-label trials cannot distinguish from placebo, adjunctive-care, or regression-to-the-mean effects.

Approaches

1. Autologous surgical reconstruction (available, rarely performed)

Operating on the patient’s own tissue — no foreign material:

  • Valvuloplasty (internal or external) — surgically tightening a stretched but present valve; valve transposition and axillary-vein valve transplantation import a competent valve segment.23
  • Neovalve construction (Maleti/Lugli technique) — fashioning a new monocusp valve from intraluminal vein-wall flaps. The original PTS series (n=16 patients/18 limbs) healed ulcers in 16/18 limbs (89%) with neovalve competence in 95%, though early thrombosis below the neovalve occurred in ~12%.4

A 2023 systematic review/meta-analysis (57 studies; only 3 RCTs, 252 patients; the rest case series, 4004 patients; database inception to Feb 2022) pooled outcomes for primary valve incompetence by technique. For internal valvuloplasty (the largest subgroup): ulcer healing 89% (95% CI 81–96%), valve competence 87% (95% CI 80–93%), valve patency 98% (95% CI 95–100%). For the neovalve technique specifically: ulcer healing 85% (95% CI 55–100%), competence 88% (95% CI 78–96%). PTS subgroups did worse across all techniques, consistent with the harder post-thrombotic substrate.5 The entire surgical literature is case-series-dominated, operator-dependent, and of low contemporary utilization. needs-replication

2. Bioprosthetic venous valves — the VenoValve (and its FDA rejection)

The VenoValve (enVVeno Medical) is a surgically-implanted monocusp bioprosthesis — a porcine non-coronary aortic valve leaflet stitched to a stainless-steel frame with a section of porcine aortic wall, sewn into the femoral vein. It was the field’s lead program. The US pivotal SAVVE trial (NCT04943172; single-arm, n=75, CEAP C4b/C4c/C5/C6) reported at 1 year: device implanted in 73/75 (97.3%); 84.6% of implanted patients achieved a clinically meaningful rVCSS improvement (mean −7.9 points among responders; mean −6.7 points all-patient); ulcer healing 91.6% for ulcers <12 months duration (77.8% improvement/healing for ulcers >12 months) — but only 34.3% achieved ≥30% improvement in duplex reflux time at 6 months, and the perioperative major-adverse-event rate was 30.7% (28 events in 23 patients; predominantly bleeding).6

Critically: the VenoValve is NOT approved. enVVeno submitted a PMA (Breakthrough Device) in Nov 2024; the FDA issued a not-approvable letter in Aug 2025, and the appeal was denied in Nov 2025 — the agency held that the device did not meet the standard of reasonable assurance of safety and effectiveness (the weak reflux-time correction + high MAE rate against a single-arm design are the likely drivers).7 A transcatheter version (enVVe/TAVVE) received an FDA IDE in April 2026 for a pivotal study that will — for the first time in this field — include a randomized standard-care arm; enrollment had not begun and no NCT was registered as of this writing.8

3. Percutaneous in-situ valve creation — BlueLeaf (suspended)

The BlueLeaf system (InterVene Inc.) formed a monocusp valve from the patient’s own vein wall percutaneously, leaving no implant. Early feasibility (n=14, CEAP 4–6): valve formed in 93%, rVCSS improved 15.0→9.4 at 360 days, 5/5 ulcers healed, no DVT — but reflux time did not decrease (popliteal RT 3.0→3.6 s).9 All InterVene trials are now TERMINATED/WITHDRAWN (“project suspended by Sponsor”); the program is dormant.

4. Tissue-engineered / decellularized valves (preclinical only)

No first-in-human exists. Approaches: small intestinal submucosa (SIS) bicuspid valves (sheep IVC, 6/8 competent at 5 weeks);10 decellularized + recellularized human femoral vein-valve allgrafts (in-vitro competency proof-of-concept);11 and the methodologically important finding that decellularization chemistry determines whether the valve still works — antigen-removal preserved function whereas SDS caused valvular insufficiency.12 Bioprinted venous valves do not appear in the primary literature. no-mechanism

Current status (May 2026)

ApproachLead exampleStatus
Bioprosthetic, surgicalVenoValve (enVVeno)Rejected — FDA not-approvable Aug 2025, appeal denied Nov 2025
Bioprosthetic, transcatheterenVVe / TAVVEInvestigational — FDA IDE Apr 2026; randomized arm planned; not yet enrolling
Percutaneous in-situBlueLeaf (InterVene)Suspended — all trials terminated/withdrawn
Autologous surgicalneovalve, valvuloplasty, transplantAvailable, rarely performed — case-series evidence (3 RCTs total)
Tissue-engineered / decellularizedSIS, decellularized allograftPreclinical only

Bottom line: there is currently no approved artificial venous valve. Autologous surgical reconstruction is the only clinically usable option and rests almost entirely on uncontrolled case series. The transcatheter enVVe pivotal — with the field’s first randomized control arm — is the study most likely to resolve whether bioprosthetic valves deliver real hemodynamic benefit. contradictory-evidence (clinical-score vs reflux-time discordance)

Relevance to early/superficial disease

For superficial truncal reflux and cosmetic varicose veins (CEAP C1–C2), valve reconstruction is not relevant — those are treated, if symptomatic, by endovenous ablation of the refluxing trunk (the body simply reroutes flow through competent deep veins). Artificial-valve technology targets the much smaller population with deep-system reflux/PTS who have failed conservative therapy. See chronic-venous-disease for the full CEAP-graded treatment ladder.

Footnotes

Footnotes

  1. doi:10.1177/0268355520962451 · Zervides C et al. · Phlebology 2021;36(2):89–101 · systematic review (35 papers) · PMID 33021138 · prosthetic venous valves 2012–2020; failure modes = regurgitation, migration, leakage; field “away from the ideal valve” ↩

  2. Raju S · Int Angiol 1985;4(4):419–424 · review/technique · PMID 3834004 · foundational description of axillary-vein valve transfer + valvuloplasty (no DOI in record) ↩

  3. doi:10.1016/j.jvsv.2014.04.013 · Verma H, Tripathi RK · J Vasc Surg Venous Lymphat Disord 2014;2(4):457–464 · technique/series · PMID 26993543 · reduction internal valvuloplasty for primary deep-vein valvular incompetence ↩

  4. doi:10.1016/j.jvs.2005.12.053 · Maleti O et al. · J Vasc Surg 2006;43(4):794–799 · case series · n=16 patients/18 limbs (PTS) · PMID 16616239 · neovalve from intraluminal flaps; ulcer healed 16/18 (89%), competence 95%, early sub-neovalve thrombosis ~12% ↩

  5. doi:10.1016/j.jvsv.2023.07.003 · Maleti O et al. · J Vasc Surg Venous Lymphat Disord 2023;11(6):1265–75 · systematic review + meta-analysis · 57 studies quantitative synthesis (3 RCTs/252 pts + 54 case series/4004 pts); database inception to Feb 2022 · PMID 37453548 · primary incompetence pooled for internal valvuloplasty: ulcer healing 89% (95% CI 81–96%), ulcer recurrence 7% (95% CI 1–17%), valve patency 98% (95% CI 95–100%), valve competence 87% (95% CI 80–93%); neovalve (5 studies): ulcer healing 85% (95% CI 55–100%), competence 88% (95% CI 78–96%); PTS subgroup (secondary incompetence) showed significantly worse outcomes across all techniques ↩

  6. doi:10.1016/j.jvsv.2025.102314 · Ochoa Chaar CI et al. · J Vasc Surg Venous Lymphat Disord 2026;14:102314 · prospective single-arm multicenter pivotal (SAVVE, NCT04943172) · n=75 enrolled (23 sites, Oct 2021–Sep 2023); median age 65 yr; 81.3% male; 58.7% C6; 74.7% post-thrombotic · PMID 40946857 · PMC12553046 · implanted 73/75 (97.3%); median baseline rVCSS 16; at 12 months: 84.6% of implanted patients achieved ≥3-pt rVCSS improvement (mean −7.9 pts among responders; −6.7 pts all-patient); ulcer healing/improvement 84% overall (91.6% for ulcers <12 mo); reflux-time ≥30% improved only 34.3% at 6 months; perioperative MAE 30.7% (28 events/23 patients; predominantly bleeding + DVT; no perioperative PE or mortality) ↩

  7. enVVeno Medical company release · https://envveno.com/envveno-receives-not-approvable-letter-from-the-fda-for-the-venovalve/ · web-retrieved 2026-05-25 · VenoValve PMA not-approvable letter Aug 2025; supervisory appeal denied Nov 2025; NOT approved · no-fulltext-access (company/FDA source, not peer-reviewed) ↩

  8. enVVeno Medical company release · https://envveno.com/envveno-medical-receives-first-ever-fda-ide-approval-for-a-u-s-pivotal-study-of-a-non-surgical-replacement-venous-valve/ · web-retrieved 2026-05-25 · enVVe (transcatheter) FDA IDE approved Apr 29 2026; pivotal (10 + 220 pts, 55 randomized to standard care); no NCT registered yet · no-fulltext-access ↩

  9. doi:10.1016/j.jvsv.2020.12.073 · Vasudevan T et al. · J Vasc Surg Venous Lymphat Disord 2021;9(2):520–527 · early feasibility (BlueLeaf) · n=14 (CEAP 4–6) · PMID 33359385 · monocusp formed in 93%; rVCSS 15.0→9.4 at 360 d (P=.0002); 5/5 ulcers healed; reflux time unchanged (3.0→3.6 s); program subsequently suspended (NCT04225806 terminated) ↩

  10. doi:10.1097/01.rvi.0000058410.01661.62 · Brountzos E et al. · J Vasc Interv Radiol 2003;14(3):349–356 · preclinical (sheep IVC) · PMID 12631640 · suspended SIS bicuspid valves; 5-week patency, 6/8 competent, host remodeling ↩

  11. doi:10.1016/j.jvsv.2014.12.002 · Kuna VK et al. · J Vasc Surg Venous Lymphat Disord 2015;3(2):209–217 · preclinical (human cadaveric, in-vitro) · PMID 26992620 · 15 decellularized + recellularized femoral vein-valve segments; retained ECM + competency to 100 mm Hg reflux ↩

  12. doi:10.1016/j.actbio.2020.03.003 · Lopera Higuita M, Griffiths LG · Acta Biomater 2020;107:115–128 · preclinical (bovine saphenous vein) · PMID 32151701 · antigen-removal decellularization preserved valve function; SDS caused valvular insufficiency — decellularization chemistry is determinative ↩

Graph View

Backlinks